Funded Biotechnology Startups in Tel Aviv
Among the 19 biotech entries listed for Tel Aviv, CytoReason’s $80M round on 2024-07-17 is the largest disclosed amount, and it sits well above the next-la…
Among the 19 biotech entries listed for Tel Aviv, CytoReason’s $80M round on 2024-07-17 is the largest disclosed amount, and it sits well above the next-largest disclosed figures (e.g., InspireMD’s $114M on 2023-05-15 is actually higher, making CytoReason the largest in the 2024 window rather than overall). The only clearly above-$50M disclosed rounds in the table are InspireMD ($114M on 2023-05-15), RedDress ($26M on 2023-05-24 does not qualify), and CytoReason ($80M on 2024-07-17), with most other disclosed rounds clustered in the single-digit to low tens of millions (e.g., MSICS Pharma $4M on 2026-05-03; SuperMeat $6M on 2026-05-12; Chemomab $10M on 2024-07-25).
The list is also date-concentrated: a dense run occurs in 2026 (multiple entries from 2026-05-11 through 2026-06-22), while earlier activity spans 2020-12-16 (Senecio Robotics) through 2024-12-03 (Purple Biotech). Geographically, 17 of 19 rows are explicitly Tel Aviv (city repeated for those tagged “Tel Aviv, Tel Aviv, Israel” and “Tel Aviv, Israel”), and the dataset is mostly “Series Unknown” or specific early-stage labels: 6 entries are labeled “Series Unknown” and 2 are explicitly “undisclosed” on amount (NanoGhosts 2026-06-22; Azura Ophthalmics 2022-09-07).
Most recent rounds
19 shownRelated listings
Frequently asked
Which disclosed rounds are outliers in size within this Tel Aviv biotech list?
In disclosed amounts, InspireMD’s $114M (2023-05-15) is the standout above the rest; CytoReason’s $80M (2024-07-17) is the next-largest disclosed figure and still markedly higher than the majority of other rounds such as Chemomab’s $10M (2024-07-25) and MSICS Pharma’s $4M (2026-05-03).
Do rounds cluster tightly in time, or are they evenly spread across years?
There are clear temporal clusters: 2026 contains multiple entries packed between 2026-05-11 and 2026-06-22 (e.g., ECOncrete $14M on 2026-05-11; RedHill Biopharma $6M on 2026-06-18; NanoGhosts with undisclosed amount on 2026-06-22), while the earliest row is 2020-12-16 (Senecio Robotics $12M), extending the visible range back four years.
How are disclosed amounts distributed, based on the smallest and typical ranges in the table?
The smallest disclosed amount is Donisi Health’s $200K grant on 2021-12-08, while most disclosed equity rounds shown are concentrated in single-digit to low double-digit millions (examples: Purple Biotech $3M on 2024-12-03; MSICS Pharma $4M on 2026-05-03; Protai $12M on 2023-03-15).
Is Tel Aviv consistently represented, or are there notable location discrepancies in the entries?
Location is highly consistent: 17 of 19 entries specify Tel Aviv, with two showing the more granular “Tel Aviv, Tel Aviv, Israel” format (NanoGhosts 2026-06-22 and MSICS Pharma 2026-05-03), but both still point to Tel Aviv. The remaining rows still list Tel Aviv in the city field (e.g., CytoReason 2024-07-17; InspireMD 2023-05-15).
What share of entries use non-specified stage labels or lack disclosed funding amounts?
Stage labeling skews toward non-specific classifications: 6 of 19 rows are marked “Series Unknown.” For amounts, 2 of 19 rows are explicitly “undisclosed” (NanoGhosts on 2026-06-22; Azura Ophthalmics on 2022-09-07), which affects comparisons of maxima and the right edge of the funding-size distribution.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.